Nomogram Based on Systemic Immune-Inflammation Index to Predict Overall Survival in Gastric Cancer Patients

Table 3

Univariate and multivariate Cox regression analyses for overall survival in patients with gastric cancer.

Variables	Univariate analysis		Multivariate analysis
	HR (95% CI)	value	HR (95% CI)	value
Primary cohort
Sex: male vs. female	1.14 (0.92–1.41)	0.223
Age: >60 vs. ≤60	1.24 (0.99–1.54)	0.053
Tumor location		0.001		0.057
Middle vs. upper	0.71 (0.54–0.93)	0.018	0.84 (0.63–1.12)	0.227
Lower vs. upper	0.58 (0.44–0.76)	<0.001	0.71 (0.53–0.95)	0.020
Grade: poorly vs. well	0.56 (0.40–0.72)	<0.001	1.12 (0.89–1.41)	0.350
Lauren type		0.137
Intestinal vs. diffuse	1.21 (0.91–1.62)	0.195
Mixed vs. diffuse	0.98 (0.72–1.34)	0.907
Tumor size: >5 vs. ≤5	2.38 (1.92–2.94)	<0.001	1.19 (0.94–1.51)	0.142
Lymphovascular: yes vs. no	1.21 (0.97–1.50)	0.086
Perineural: yes vs. no	1.58 (1.29–1.93)	<0.001	1.21 (0.96–1.53)	0.101
TNM stage		<0.001		<0.001
II vs. I	2.03 (1.46–2.83)	<0.001	1.77 (1.26–2.47)	0.001
III vs. I	4.68 (3.46–6.34)	<0.001	3.10 (2.27–4.24)	<0.001
Chemotherapy: Yes vs. No	1.12 (0.91–1.37)	0.282
SII: >320 vs. ≤320	2.47 (2.01–3.04)	<0.001	1.61 (1.27–2.05)	0.041
NLR: >1.3 vs. ≤1.3	1.79 (1.47–2.20)	<0.001	1.25 (0.99–1.58)	0.054
PLR: >135 vs. ≤135	1.82 (1.46–2.27)	<0.001	1.04 (0.81–1.33)	0.787
MLR: >0.23 vs. ≤0.23	1.88 (1.54–2.31)	<0.001	1.17 (0.93–1.47)	0.183
Validation cohort
Sex: male vs. female	1.01 (0.62–1.63)	0.987
Age: >60 vs. ≤60	1.09 (0.88–1.36)	0.442
Tumor location		0.046		0.098
Middle vs. upper	0.51 (0.29–0.89)	0.018	0.61 (0.30–1.41)	0.146
Lower vs. upper	0.51 (0.27–0.94)	0.032	0.65 (0.38–1.10)	0.087
Grade: poorly vs. well	1.25 (1.01–1.54)	0.041	1.48 (0.95–2.29)	0.080
Lauren type		0.386
Intestinal vs. diffuse	0.65 (0.34–1.25)	0.196
Mixed vs. diffuse	0.99 (0.63–1.57)	0.979
Tumor size: >5 vs. ≤5	1.72 (1.09–2.70)	0.019	1.81 (0.81–4.04)	0.151
Lymphovascular: yes vs. no	1.48 (0.90–2.43)	0.118
Perineural: yes vs. no	1.70 (1.06–2.72)	0.028	1.43 (0.61–3.39)	0.414
TNM stage		<0.001		<0.001
II vs. I	2.91 (1.45–5.83)	0.003	3.19 (1.43–3.63)	0.002
III vs. I	7.12 (3.50–14.50)	<0.001	7.05 (3.15–15.81)	<0.001
Chemotherapy: yes vs. no	1.26 (0.79–2.01)	0.001
SII: >320 vs. ≤320	2.75 (1.75–4.32)	<0.001	2.94 (1.83–4.73)	<0.001
NLR: >1.3 vs. ≤1.3	2.03 (1.23–3.35)	0.006	1.71 (0.96–3.39)	0.067
PLR: >135 vs. ≤135	1.90 (1.24–2.94)	0.004	1.46 (0.93–2.30)	0.102
MLR: >0.23 vs. ≤0.23	1.56 (1.02–2.40)	0.046	1.22 (0.76–1.95)	0.420